Guggenheim analyst issues BUY recommendation for OVID on October 5, 2026 08:16PM ET. OVID was trading at $2.34 at issue of the analyst recommendation.The overall analyst consensus : BUY.Current analyst recommendations are : 11 - Buy, 3 - Hold recommendations .Historical Analyst RecommendationsLatest 10 recommendationsReport DateAnalyst CompanyActionPrevious GradeNew GradePrice when posted 2026-10-05 Guggenheim Initialise Buy...
Comtech Telecommunications Corp. (CMTL) confirmed earnings release on October 06, 2026, Before the market for the...
VCI Global Limited (VCIG) confirmed earnings release on October 06, 2026, Before the market for the...
Toro Corp. (TORO) confirmed earnings release on October 06, 2026, Before the market for the quarter...
Beneficient (BENF) confirmed earnings release on October 05, 2026, Before the market for the quarter ending...
Madison El-Saadi from B.Riley Financial issued a price target of $160.00 for SPRB on 2026-10-05 09:07:00.The adjusted price target was set to $160.00.At the time of the announcement, SPRB was...
David Nierengarten from Wedbush issued a price target of $14.00 for STTK on 2026-10-02 11:42:04.The adjusted price target was set to $14.00.At the time of the announcement, STTK was trading...
Joseph Stringer from Needham issued a price target of $19.00 for STTK on 2026-10-02 11:05:00.The adjusted price target was set to $19.00.At the time of the announcement, STTK was trading...
Manuel Navas from Piper Sandler issued a price target of $12.00 for MFIN on 2026-10-02 10:59:49.The adjusted price target was set to $12.00.At the time of the announcement, MFIN was...
from Guggenheim issued a price target of $5.00 for FHTX on 2026-10-02 10:49:43.The adjusted price target was set to $5.00.At the time of the announcement, FHTX was trading at $2.92.The...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
